. 2017 Mar 13;7(2):439–447. doi: 10.1177/2045893217702401
© The Author(s) 2017
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Fig. 1.
Comparison between the CT and PT group in terms of maximal dose of epoprostenol.